Tech Company Financing Transactions
Turing Pharmaceuticals Funding Round
Private investors invested in a $90 million Series A funding round for Turing Pharmaceuticals. The financing round was announced on 8/12/2015.
Transaction Overview
Company Name
Announced On
8/12/2015
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$90,000,000
Round
Series A
Investors
private investors (Lead Investor) (Martin Shkreli)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1177 Ave. of the Americas 39th Floor
New York, NY 10036
USA
New York, NY 10036
USA
Phone
Website
Email Address
Overview
Turing is a fully integrated biopharmaceutical company focusing on patients with unmet medical needs. We are dedicated to helping patients, who often have limited or no effective treatment options, by developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ron Tilles
VP - General Counsel
Eve Costopoulos
VP - R & D
Eliseo Salinas
Browse more venture capital transactions:
Prev: 8/12/2015: Speech Buddies venture capital transaction
Next: 8/13/2015: Carta venture capital transaction
Share this article
About Our VC Transactions Data
We document funding rounds that are announced publicly. VC transactions on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs